Oncologists Grapple With Sequencing, Access as Treatments Multiply

Oncologists face complex challenges in sequencing and accessing an expanding array of targeted cancer therapies, including BTK inhibitors for chronic lymphocytic leukemia (CLL) and multiple antibody-drug conjugates (ADCs) for breast cancer, complicated by insurance barriers and social determinants of health. Specialty pharmacy navigators and tailored treatment decisions based on patient risk factors and preferences are critical to managing therapy choices and improving patient access.

This Wire brief sits within Fusion42's coverage of Health.